



ELEKTA'S NOMINATION COMMITTEE APPOINTED

PRESS RELEASE

Stockholm, Sweden, January 16, 2006

In accordance with the decision at the Annual General Meeting on September 21, 2005, Elekta's Board Chairman Akbar Seddigh contacted the company's largest shareholders during December and January to form a Nomination Committee. Consequently, the shareholders agreeing to participate in the work of the Nomination Committee each nominated a representative.

The Nomination Committee will form a proposal to the Board of Directors and prepare other matters prior to the Annual General Meeting on September 20, 2006.

The shareholders and representatives comprising the Nomination Committee are:

SEB Funds, Ann Ahlberg
Robur Funds, Åsa Nisell
Carnegie Funds, Henrik Rhenman
AMF Pension, Tor Marthin
Laurent Leksell

Combined, on December 31, 2005, these shareholders represented 42 percent of the votes in Elekta AB.

The Nomination Committee will elect a Chairman from among its members and its assignment remains effective until a new Nomination Committee is appointed.

For further information, please contact:

Peter Ejemyr
Group VP Corporate Communications, Elekta AB
Tel: +46 733 611 000
e-mail: peter.ejemyr@elekta.com

About Elekta

Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.

Clinical solutions include among others Leksell Gamma Knife[®] for non-invasive treatment of brain surgery and Elekta Synergy[®] for image guided radiation therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, the Elekta Group is the world's largest supplier of oncology software.

Elekta's systems and solutions are used at over 3,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders.

With approx. 1700 employees, Elekta's corporate headquarter is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTA. For more information about Elekta, please visit www.elekta.com.